Belén Aparicio De La Torre-rekin lankidetzan egindako argitalpenak (12)

2024

  1. Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2023

  1. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  2. Epitope identification for subunit vaccine design: application to prophylactic vaccines against SARS-CoV-2 and therapeutic vaccines against cancer

    Epitope identification for subunit vaccine design: application to prophylactic vaccines against SARS-CoV-2 and therapeutic vaccines against cancer

  3. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  4. Mutated trimeric RBD vaccines: a platform against variants of concern

    Signal Transduction and Targeted Therapy

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  4. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

2021

  1. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18